The U.S. Food and Drug Administration approved on Tuesday the first drug under its new fast-track program designed to shorten ...

Pilatus Biosciences Announces FDA Clearance of IND Application for PLT012, a First-in-Class Anti-CD36 Metabolic Checkpoint ...

An announcement from Praxis Precision Medicines ( ($PRAX) ) is now available. On December 9, 2025, Praxis Precision Medicines ...

If approved, CUTX-101 will be the first and only FDA-approved treatment available for Menkes disease, a rare X-linked ...

Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a ...

FDA Commissioner Dr. Marty Makary announces the acceptance of broader real-world data in medical applications, ending previous requirements that limited submissions.

Wockhardt's shares jumped 19.3% to ₹1,473 following the US FDA's acceptance of its antibiotic drug Zaynich's New Drug Application. The pharma shares have remained under pressure since hitting a ...

Disc Medicine Inc. (NASDAQ: IRON) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, ...

Wockhardt's share price surged 6.5% following FDA acceptance of its New Drug Application for Zaynich, marking a significant ...

We found that one-third of pharmaceutical companies proactively released the launch price of their medications between 2022 and 2024, and another third released them reactively. Smaller public ...

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis ...

Abivax receives a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ...